SCHEMBL3460182

SCHEMBL3460182

Cc1nn(-c2ccccn2)c(C)c1S(=O)(=O)Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
ALDH1A1 P00352 4/20 0.48
HSD17B10 Q99714 2/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
KDM4E B2RXH2 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
CCNA2 P20248 6/20 0.43
CDK2 P24941 6/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
THRB P10828 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.41
CCNO P22674 1/20 0.41
CCNE1 P24864 1/20 0.41
CCNA1 P78396 1/20 0.41
P2RX7 Q99572 1/20 0.40
GAA P10253 1/20 0.39
SPR P35270 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10516482 0.85 MAPT (0.52) MAPTALDH1A1HSD17B10HPGDALOX15
SCHEMBL3462043 0.85 KDM4E (0.63) MAPTALDH1A1HSD17B10HPGDALOX15
SCHEMBL3007153 0.78 KDM4E (0.71) MAPTALDH1A1HPGDALOX15KDM4E
SCHEMBL18949733 0.77 ALDH1A1 (0.55) MAPTALDH1A1HSD17B10HPGDALOX15
SCHEMBL123248 0.77 ALDH1A1 (0.52) MAPTALDH1A1HSD17B10HPGDALOX15
SCHEMBL7506607 0.74 SMN1; SMN2 (0.59) MAPTALDH1A1HSD17B10HPGDALOX15
SCHEMBL27140538 0.73 MAPT (0.51) MAPTALDH1A1HPGDKDM4ETDP1
SCHEMBL27780413 0.73 ALDH1A1 (0.51) MAPTALDH1A1HSD17B10HPGDALOX15
SCHEMBL10556252 0.72 MAPT (0.46) MAPTALDH1A1HSD17B10HPGDALOX15
SCHEMBL16019533 0.72 ALDH1A1 (0.50) MAPTALDH1A1HSD17B10HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B MAPT 2831/4885ALDH1A1 838/4885HSD17B10 4675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.